Table 2.

Baseline characteristics of patients with bDNA according to the use of NSBB

Demographics	NSBB group (n=11)	Non-NSBB group (n=11)	P value
Age (years) (IQR)	57 (51–68)	51 (44–56)	0.14
Gender, % (n)			0.65
Male sex	63.6 (7/11)	72.7 (8/11)
Female sex	36.4 (4/11)	27.3 (3/11)
Aetiology, % (n)
Alcoholic liver disease	54.5 (6/11)	72.7 (8/11)	0.38
Viral hepatitis (hepatitis B or C)	27.3 (3/11)	9.1 (1/11)	0.27
Non-alcoholic steatohepatitis	18.2 (2/11)	18.2 (2/11)	1.00
Model For End-Stage Liver Disease score (IQR)	14.9 (11.4–19.9)	14.5 (12.7–23.1)	0.72
Comorbidities, % (n)
Ischaemic heart disease	9.1 (1/11)	9.1 (1/11)	1.00
Lung disease	18.2 (2/11)	18.2 (2/11)	1.00
Diabetes mellitus	36.4 (4/11)	18.2 (2/11)	0.34
Primary infection site, % (n)
Spontaneous bacteraemia	27.3 (3/11)	36.4 (4/11)	0.65
Spontaneous bacterial peritonitis	18.2 (2/11)	9.1 (1/11)	0.53
Respiratory infection	27.3 (3/11)	18.2 (2/11)	0.61
Cellulitis	–	18.2 (2/11)	–
Urinary tract infection	18.2 (2/11)	–	–
Other abdominal infections	9.1 (1/11)	18.2 (2/11)	0.53

bDNA, bacterial DNA; NSBB, non-selective beta blocker.